1 / 5

The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers

The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers. Background. Inhibiting polyADP polymerase is key in the treatment of cancers that have DNA-repair defects. Methods.

adler
Télécharger la présentation

The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Inhibition of Polymerase in Tumors from BRCA Mutation Carriers

  2. Background • Inhibiting polyADP polymerase is key in the treatment of cancers that have DNA-repair defects

  3. Methods • A phase 1 trial of the pharmacokinetic and pharmacodynamics traits of olaparib was done and aimed at studying carriers of BRCA1 and BRCA2.

  4. Results • 60 patients were treated; 20 of them were carriers of either BRCA1 or BRCA2 mutations. Objective antitumor activity was reported in mutation carriers, all of which had ovarian, breast, or prostate cancer and got several treatment regimens.

  5. Conclusion • Olaparib has antitumor activity associated with BRCA1 and BRCA2 mutations.

More Related